"This transaction will bring additional value to our customers, further reinforcing EW Nutrition’s global market position, and increasing its product portfolio and geographical reach,” said managing director Michael Gerrits.
“The products acquired will further support EW Nutrition’s mission to mitigate the impact of antimicrobial resistance by providing comprehensive animal nutrition solutions," he said.
Dan Meagher, president and chief executive officer of Novus International, Inc., said the sale is part of Novus’s Project Destiny, a multi-year plan to transform the company into the industry’s leading provider in animal health through nutrition solutions by focusing its resources on core platforms and emerging technologies.
“We are pleased to have found a committed owner for these platforms so that they may continue bringing value to the industry,” said Meagher, and “we are excited to focus our energies on developing new, innovative technologies into meaningful nutrition solutions for our customers.”
Novus products are Acidomatrix, Activate, Avimatrix, Cibenza, MFP and MFA and Alimet, which feature methionine.
They also market four mineral supplements – Mintrex, MAAC, Provenia and Sporulin.